Holen Sie sich die Stockscreener-App
44.81
3.13%
-1.45
Handel nachbörslich:
44.81
Schlusskurs vom Vortag:
$46.26
Offen:
$45.69
24-Stunden-Volumen:
944.38K
Relative Volume:
1.30
Marktkapitalisierung:
$2.84B
Einnahmen:
-
Nettoeinkommen (Verlust:
$-107.85M
KGV:
-13.34
EPS:
-3.36
Netto-Cashflow:
$-106.82M
1W Leistung:
-7.93%
1M Leistung:
+8.87%
6M Leistung:
+8.26%
1J Leistung:
+227.32%
1-Tages-Spanne:
$43.41
$46.70
1-Wochen-Bereich:
$43.41
$51.61
52-Wochen-Spanne:
$12.28
$51.61
Vera Therapeutics Inc Stock (VERA) Company Profile
Firmenname
Vera Therapeutics Inc
Sektor
Branche
Telefon
650-770-0077
Adresse
2000 SIERRA POINT PARKWAY, SUITE 1200, BRISBANE
Vergleichen Sie VERA mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
| VERA | 44.81 | 2.84B | 0 | -107.85M | -106.82M | -3.36 |
| VRTX | 467.01 | 119.87B | 10.63B | -479.80M | -1.35B | 13.33 |
| REGN | 762.00 | 83.27B | 13.85B | 4.65B | 3.32B | 35.06 |
| ARGX | 567.90 | 33.96B | 1.86B | -40.29M | -1.28B | -4.16 |
| ALNY | 232.27 | 30.18B | 2.09B | -332.26M | 16.06M | -4.14 |
| BNTX | 101.87 | 24.42B | 3.30B | -501.07M | 1.03B | 11.54 |
Vera Therapeutics Inc Stock (VERA) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2024-01-25 | Eingeleitet | Oppenheimer | Outperform |
| 2024-01-08 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2023-12-18 | Eingeleitet | Raymond James | Outperform |
| 2023-11-10 | Hochstufung | Jefferies | Hold → Buy |
| 2023-08-16 | Eingeleitet | Guggenheim | Buy |
| 2023-01-04 | Herabstufung | Jefferies | Buy → Hold |
| 2023-01-04 | Herabstufung | Wedbush | Outperform → Neutral |
| 2022-07-12 | Eingeleitet | JP Morgan | Overweight |
| 2022-05-02 | Eingeleitet | H.C. Wainwright | Buy |
| 2022-04-19 | Eingeleitet | Wedbush | Outperform |
Alle ansehen
Vera Therapeutics Inc Aktie (VERA) Neueste Nachrichten
Vera Therapeutics Appoints Jason S. Carter as Chief Legal Officer - GlobeNewswire
Vera Therapeutics Appoints Former Kite Pharma Legal Head as Chief Legal Officer | VERA Stock News - StockTitan
(VERA) Proactive Strategies - Stock Traders Daily
COMMODORE CAPITAL LP Adjusts Stake in Vera Therapeutics Inc - GuruFocus.com
Kynam Capital Management, LP Increases Stake in Vera Therapeutics Inc - GuruFocus.com
Vera Therapeutics stock soars to all-time high of $50.98 - Investing.com
Vera Therapeutics stock soars to all-time high of $50.98 By Investing.com - Investing.com Australia
Vera Therapeutics (NASDAQ:VERA) Reaches New 1-Year HighHere's What Happened - MarketBeat
FMR LLC Reduces Stake in Vera Therapeutics Inc - GuruFocus.com
Vera Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
Vera Therapeutics Awards $45.17 Stock Options to New Hires in Growth Push | VERA Stock News - StockTitan
Wall Street Analysts Think Vera Therapeutics (VERA) Could Surge 27.26%: Read This Before Placing a Bet - Yahoo Finance
Vera Therapeutics Partners with University of Michigan on the NEPTUNE Match Project and PIONEER Study - The Manila Times
Vera Therapeutics (NASDAQ:VERA) Posts Quarterly Earnings Results, Misses Expectations By $0.21 EPS - MarketBeat
Vera Therapeutics to Participate at Upcoming Investor Conferences - GlobeNewswire
Vera Therapeutics to Present at Two Major Healthcare Investor Conferences | VERA Stock News - StockTitan
Vera Therapeutics (NASDAQ:VERA) Price Target Raised to $38.00 - MarketBeat
Vera Therapeutics Advances in Autoimmune Treatment - TipRanks
Vera Therapeutics Provides Business Update and Reports Third Quarter 2024 Financial Results - The Manila Times
Vera Therapeutics, Inc. (NASDAQ:VERA) Given Average Rating of "Buy" by Brokerages - MarketBeat
JPMorgan Chase & Co. Boosts Vera Therapeutics (NASDAQ:VERA) Price Target to $75.00 - MarketBeat
Trading (VERA) With Integrated Risk Controls - Stock Traders Daily
Vera Therapeutics (NASDAQ:VERA) Shares Up 7.3%Here's Why - MarketBeat
Vera Therapeutics announces proposed public offering of class A common stock - MSN
Vera Therapeutics director Beth Seidenberg sells shares for $720,493 - Investing.com India
Vera Therapeutics director Beth Seidenberg sells shares for $720,493 By Investing.com - Investing.com Canada
Vera Therapeutics (NASDAQ:VERA) Sees Large Volume IncreaseHere's What Happened - MarketBeat
Vera Therapeutics (NASDAQ:VERA) PT Raised to $64.00 at Guggenheim - Defense World
Vera Therapeutics Announces Pricing of Public Offering of Class A Common Stock - GlobeNewswire
Vera Therapeutics (NASDAQ:VERA) Shares Gap DownHere's Why - MarketBeat
Vera Therapeutics price target raised to $64 from $56 at Guggenheim - Yahoo Finance
SEC Form 424B5 filed by Vera Therapeutics Inc. - Quantisnow
Vera Therapeutics Announces Proposed Public Offering of Class A Common Stock - The Manila Times
Vera Therapeutics (NASDAQ:VERA) Price Target Raised to $64.00 - MarketBeat
Vera Therapeutics' Atacicept Shows Sustained, Substantial Improvement In Kidney Function For Patients At Almost Two Years - AOL
Vera Therapeutics (NASDAQ:VERA) Shares Gap UpHere's What Happened - MarketBeat
Vera Therapeutics Shares Climb 14% on Positive Results in Kidney Disease Study - MarketWatch
PROCEPT BioRobotics Posts Strong Q3 Earnings, Joins Monte Rosa Therapeutics, EyePoint Pharmaceuticals And Other Big Stocks Moving Higher On Monday - Benzinga
Vera reports long-term atacicept data at Kidney Week 2024 - The Pharma Letter
VERAVera Therapeutics, Inc. Latest Stock News & Market Updates - StockTitan
Vera Therapeutics Announces 96-week eGFR Stabilization in ORIGIN Phase 2b Study of Atacicept in IgAN in a Late-Breaking Oral Presentation at the American Society of Nephrology Kidney Week 2024 - The Manila Times
Vera Therapeutics Announces 96-week eGFR Stabilization in - GlobeNewswire
Marshall Fordyce Sells 19,375 Shares of Vera Therapeutics, Inc. (NASDAQ:VERA) Stock - MarketBeat
Vera Therapeutics CEO sells shares worth $782,610 By Investing.com - Investing.com South Africa
Vera Therapeutics CEO sells shares worth $782,610 - Investing.com
Trend Tracker for (VERA) - Stock Traders Daily
Markel Corp (MKL-N) QuotePress Release - The Globe and Mail
Finanzdaten der Vera Therapeutics Inc-Aktie (VERA)
Umsatz
Nettogewinn
Free Cashflow
ENV
3.66%
1.11%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):